8-Cyclopentyl-1,3-dimethylxanthine
CAS No. 35873-49-5
8-Cyclopentyl-1,3-dimethylxanthine( 8-Cyclopentyl-1,3-dimethylxanthine? | CPT )
Catalog No. M27866 CAS No. 35873-49-5
8-Cyclopentyl-1,3-dimethylxanthine?is a potent antagonist of adenosine A1 receptor.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
Size | Price / USD | Stock | Quantity |
5MG | 45 | Get Quote |
|
10MG | 53 | Get Quote |
|
25MG | 95 | Get Quote |
|
50MG | 137 | Get Quote |
|
100MG | 194 | Get Quote |
|
200MG | 293 | Get Quote |
|
500MG | 439 | Get Quote |
|
1G | Get Quote | Get Quote |
|
Biological Information
-
Product Name8-Cyclopentyl-1,3-dimethylxanthine
-
NoteResearch use only, not for human use.
-
Brief Description8-Cyclopentyl-1,3-dimethylxanthine?is a potent antagonist of adenosine A1 receptor.
-
Description8-Cyclopentyl-1,3-dimethylxanthine?is a potent antagonist of adenosine A1 receptor.
-
In Vitro——
-
In Vivo——
-
Synonyms8-Cyclopentyl-1,3-dimethylxanthine? | CPT
-
PathwayApoptosis
-
TargetAdenosine Receptor
-
Recptor——
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number35873-49-5
-
Formula Weight248.286
-
Molecular FormulaC12H16N4O2
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 20 mg/mL (80.55 mM)
-
SMILESCn1c2nc([nH]c2c(=O)n(C)c1=O)C1CCCC1
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.Tomiyama, Tsuyoshi; Tomiyama, Akira; Kubota, Koichi. Benzofuran and benzothiophene derivatives, and a pharmaceutical containing them. Ger. Offen. (1984), DE 3332162 A1 19840419.
molnova catalog
related products
-
BAY 60-6583
BAY 60-6583 (BAY606583) is a potent, selective adenosine A2B receptor agonist with EC50 of 2.83 nM.
-
GS-6201
GS-6201 is a selective antagonist of adenosine A2B receptor. GS-6201 shows high affinity and selectivity for the human adenosine A2B receptors with a Ki of 22 nM.
-
SCH-58261
SCH-58261 is a potent and selective, competitive A2A adenosine receptor antagonist with Ki of 2.3 nM and 2.0 nM in rat and bovine brain, respectively.